Cell No. : Cell Name
HPS0164 :
update : 2021/04/05
|
| Comment | Disease specific iPS cell line derived from a patient : Muscular dystrophy, Duchenne type. iPS cells were created using the Sendai virus vector. Order Form (C-0042, C-0057, C-0007 or C-0007p). |
| Comment from the depositor | |
| Terms and conditions | 1) The iPS cells created using the Sendai virus vector are now available must be observed when using SeV-iPS cells. 2) In relation to the for-profit organizations, please contact iPS Academia Japan, Inc., prior to the utilization of iPS cells. 3) The RECIPIENT of BIOLOGICAL RESOURCE shall obtain a prior written consent on use of it from the DEPOSITOR. |
| Remarks | |
| Order Form |
Order Form(C-0042.pdf)
Approval Form(C-0057.pdf)
MTA(C-0007.pdf)
MTA(C-0007p.pdf)
|
|
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
|
|
|
Basic information
|
Animal |
_human
< Mammals
|
| Genus |
Homo
|
| Species |
sapiens
|
| Race |
Japanese
|
| Gender |
Male
|
| Age at sampling |
10s
|
| Tissue |
skin
|
| Disease name |
Muscular dystrophy, Duchenne type
|
| Classification |
iPS
|
| Recombinant |
recombinant
|
| Exogene |
SeV18+HS-OCT3/4/TSΔF, SeV18+HS-SOX2/TSΔF, SeV18+HS-KLF4/TSΔF, SeV18(HNL)c-MYCQC/TSΔF
|
|
Lifespan |
infinite
|
| Morphology |
ES-like
|
|
| |
deposit info |
lot info |
|
Medium |
Medium List |
|
Culture type |
|
Adherent cells
|
| Medium and additives |
|
DMEM/HamF12 (2mM L-Glutamine) + 20% KSR + 0.1mM NEAA + 0.1mM 2-Mercaptoethanol + 5ng/ml human basic FGF
|
| Antibiotics |
|
Free
|
|
Passage method |
|
0.25% trypsin + 0.1% collagenase type IV + 20% KSR + 1mM CaCl2 + PBS(-)
|
| Coating dish |
|
0.1% gelatin coated dish
|
Culture information
|
Passage ratio |
|
1 : 3-5 split
|
| SC frequency |
|
Subculture : once/4-6 days, Medium Renewal : every day
|
| Temperature |
|
37
℃
|
| CO2 concentration |
|
3
%
|
| Feeder cells |
|
MEF
|
| Feeder treatment |
|
X-rays 5000R (or MMC)
|
| Feeder seed cells |
|
3-5 x 10^(5) cells/60 mm dish
|
| Freeze medium |
|
DAP213 : Medium + 2M DMSO + 1M Acetamide + 3M Propyleneglycol
|
| Freezing method |
|
Vitrification
|
| Mycoplasma |
|
(-)
|
| STR(human) |
|
OK
|
| Images |
deposit info | lot info |
|
|
|
| Relational File |
deposit info | lot info |
|
|
|
| Reference information |
Reference |
0
|
| User's Publication |
2
|
| User's Publication |
|
10738
Long C, Li H, Tiburcy M, Rodriguez-Caycedo C, Kyrychenko V, Zhou H, Zhang Y, Min YL, Shelton JM, Mammen PPA, Liaw NY, Zimmermann WH, Bassel-Duby R, Schneider JW, Olson EN.
Correction of diverse muscular dystrophy mutations in human engineered heart muscle by single-site genome editing.
Sci Adv
2018
4:eaap9004
PubMed ID: 29404407
|
|
10265
Zhang Y, Long C, Li H, McAnally JR, Baskin KK, Shelton JM, Bassel-Duby R, Olson EN.
CRISPR-Cpf1 correction of muscular dystrophy mutations in human cardiomyocytes and mice.
Sci Adv
2017
3:e1602814
PubMed ID: 28439558
|
Back
Top
CELL BANK Website
SDS_DAP(MEM)_Japanese.pdf